众所周知,M1/M2巨噬细胞平衡极化决定着器官在炎症或损伤中的命运。当感染或炎症严重到足以影响一个器官时,巨噬细胞首先表现出M1表型,释放TNF-α, IL-1β, IL-12和IL-23对抗刺激。但是,如果M1期继续,就会造成组织损伤。因此,M2巨噬细胞分泌大量IL-10和TGF-β抑制炎症,有助于组织修复、重塑、血管新生和保持稳...
促进炎症的巨噬细胞称为 M1 巨噬细胞,而减少炎症和促进组织修复的巨噬细胞称为 M2 巨噬细胞。这种差异反映在它们的代谢上; M1 巨噬细胞具有将精氨酸代谢为“杀手”分子一氧化氮的独特能力,而 M2 巨噬细胞具有将精氨酸代谢为“修复”分子鸟氨酸的独特能力。 然而,随着进一步的复杂性被发现,这种二分法最近受到了...
巨噬细胞通常存在于两个不同的亚群: 1)经典激活或M1巨噬细胞,它们是促炎细胞,并被脂多糖(LPS)单独或与Th1细胞因子(如IFN-γ,GM-CSF)联合极化,并产生促炎细胞因子,如白细胞介素-1β (IL-1β), IL-6, IL-12, IL-23和TNF-α; 2)交替激活或M2型巨噬细胞,具有抗炎和免疫调节作用,被Th2细胞因子IL-4...
M1型巨噬细胞在体内主要起到吞噬细菌等外来物质及凋亡细胞碎片等内源性物质,起到保护组织器官免受外来物质侵袭。在炎症性疾病中,M1型巨噬细胞在早期炎症部位富集,并被LPS,TNFα,IFNγ等促炎因子激活,并随后通过分泌IL12等炎症因子的方式促进炎症的发生发展,保护机体免受外来物质侵袭。而在炎症后期,M2细胞则起到了...
Similar to the M1 story, M2 is to macrophages as Th2 is to lymphocytes; Th2 cells can produce high levels of IL-4, IL-13 and sometimes IL-10. While all three cytokines can induce M2 activation in macrophages, there are distinct differences in the resultant phenotypes, so we will concern...
致力于开发CAR-Macrophage疗法用以治疗肿瘤,直至2020年,他们发表研究性论文报道采用靶向HER2的CAR对巨噬细胞进行改造,并使用小鼠模型验证了CAR-Macrophage细胞对肿瘤的良好杀伤效果,并发现HER2-CAR-M能够将M2巨噬细胞转化为M1巨噬细胞,诱导炎症性肿瘤微环境,增强T细胞的抗肿瘤细胞毒性,因此这也体现了CAR-Macrophage能够在...
也可以通过qPCR，ELISA等研究方法研究IL10，TNFα等炎症因子表达水平分析M1，M2细胞类群分类比例。具体marker选择可以参考相关网站： https://www.biocompare.com/Editorial-Articles/566347-A-Guide-to-Macrophage-Markers/ 。4.1、巨噬细胞亚型在炎症疾病中研究 M1型巨噬细胞在体内主要起到吞噬细菌等外来...
Classical M1 and alternative M2 activation of macrophages, mirroring the Th1-Th2 polarization of T cells, represent two extremes of a dynamic changing state of macrophage activation. M1-type macrophages release cytokines that inhibit the proliferation of surrounding cells and damage contiguous tissue, ...
1). Apart from M0 and M2, we found inflammatory/activated macrophages in at least three different states: two transcriptionally different M1 populations (M1 ACOD1 and M1 CXCL5) and the IDA macrophage cluster, in addition to a population of inflammatory monocytes. Comparison of these inflammation-...
M1 and M2 characteristic CD markers were analysed in RAW 264.7 cells, along with key inflammatory mediators, i.e. NO, ROS, COX-2 and cytokines following LPS treatment combined with the aqueous or the ethanolic S. frutescens extract. The regulation of mitogen activated protein kinases (MAPKs) ...